Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “RDX013 is an experimental drug that is a potassium secretagogue”In the company’s words, NCT04780841 on ClinicalTrials.gov
- Tested for
- Hyperkalemia
- Main trialPhase 2
- “The purpose of this study is to evaluate the ability of RDX013 to lower serum potassium in patients with chronic kidney disease with elevated serum potassium levels”In the company’s words, NCT04780841 on ClinicalTrials.gov
Other drugs for Hyperkalemia
- WS016Waterstone Pharmaceutical (Wuhan) Co., LTD. · Phase 3
- PatiromerVifor Pharma, Inc. · Relypsa, Inc. · Phase 2
- Sodium Zirconium CyclosilicateAstraZeneca · Marketed (Phase 4 trial)
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 28 Dec 2021 | A Study Evaluating the Safety and Efficacy of RDX013 for the Treatment of Hyperkalemia |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026